Ironwood Pharmaceuticals
IRWD
149 hedge funds and large institutions have $2.35B invested in Ironwood Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 57 reducing their positions, and 25 closing their positions.
144% more call options, than puts
Call options by funds: $17M | Put options by funds: $6.95M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3% more capital invested
Capital invested by funds: $2.29B → $2.35B (+$59M)
1.95% less ownership
Funds ownership: 134.79% → 132.84% (-1.9%)
6% less funds holding
Funds holding: 158 → 149 (-9)
20% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 25
33% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$82.5M |
| 2 |
O
OppenheimerFunds
New York
|
+$38.5M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$25.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.1M |
| 2 |
O
OrbiMed
New York
|
-$23.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$20M |
| 4 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$18.4M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$11.9M |
IRWD Hedge Fund Activity: Q1 2018 in Review
149 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2018, worth a combined $2.35B — up 2.6% from $2.29B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of IRWD and 20 opened new positions — a net loss of 5 holders — while 57 trimmed existing stakes and 38 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $82.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $84.1M.
- 149 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2018, down from 158 in Q4 2017.
- Funds reported $2.35B of Ironwood Pharmaceuticals stock for Q1 2018, up 2.6% quarter-over-quarter.
- 20 funds opened new Ironwood Pharmaceuticals positions in Q1 2018 and 25 closed out, a net change of -5 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2018 was BVF Inc, an estimated $82.5M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2018 was T. Rowe Price Associates, an estimated $84.1M sold.
Based on aggregated 13F filings for Q1 2018.